RA CAPITAL MANAGEMENT, LLC Insider Trading Transactions
Get free email notifications about insider trading for RA CAPITAL MANAGEMENT, LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of RA CAPITAL MANAGEMENT, LLC. RA CAPITAL MANAGEMENT, LLC is 10% Owner in LIPID SCIENCES INC/ ($LIPD) and 10% Owner in TG THERAPEUTICS, INC. ($TGTX) and Director in KalVista Pharmaceuticals, Inc. ($CBYL) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and Director in Dicerna Pharmaceuticals Inc ($DRNA) and Director in Kala Pharmaceuticals, Inc. ($KALA) and Director in Ra Pharmaceuticals, Inc. ($RARX) and 10% Owner in Verastem, Inc. ($VSTM) and 10% Owner in Forma Therapeutics Holdings, Inc., ($FMTX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and in G1 Therapeutics, Inc. ($GTHX) and 10% Owner in Synthorx, Inc. ($THOR) and 10% Owner in scPharmaceuticals Inc. ($SCPH) and Director in Wave Life Sciences Ltd. ($WVE) and 10% Owner in Vaxcyte, Inc. ($PCVX) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and in ARVINAS INC. ($ARVN) and 10% Owner in Iterum Therapeutics plc ($ITRM) and 10% Owner in IMARA Inc. ($IMRA) and Director in Satsuma Pharmaceuticals, Inc. ($STSA) and 10% Owner in Inozyme Pharma, Inc. ($INZY) and 10% Owner in PMV Pharmaceuticals, Inc. ($PMVP) and Director in Solid Biosciences Inc. ($SLDB) and Director in Eidos Therapeutics, Inc. ($EIDX) and 10% Owner in Inhibrx, Inc. ($INBX) and 10% Owner in Orchard Therapeutics plc ($ORTX) and Director in Orchard Therapeutics plc ($ORTX) and Director in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and Director in Nkarta, Inc. ($NKTX) and 10% Owner in Phathom Pharmaceuticals, Inc. ($PHAT) and Director in 89bio, Inc. ($ETNB) and 10% Owner in Pandion Therapeutics, Inc. ($PAND) and 10% Owner in iTeos Therapeutics, Inc. ($ITOS) and Director in iTeos Therapeutics, Inc. ($ITOS) and Director in Vor Biopharma Inc. ($VOR) and 10% Owner in Dyne Therapeutics, Inc. ($DYN).
Latest Insider Trading Transactions of RA CAPITAL MANAGEMENT, LLC
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ETNB, ACRS, ARVN, DRNA, DYN, EIDX, FMTX, GTHX, IMRA, INBX, INZY, ITOS, ITRM, KALA, KALV, LIPD, NKTX, ORTX, PAND, PHAT, PMVP, RARX, RYTM, STSA, SCPH, SLDB, THOR, TGTX, PCVX, VSTM, VOR, WVE, HOWL
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 06 2021 | HOWL | Werewolf Therapeut ... | RA CAPITAL MANAGEMENT, L.P. | Director | Option Exercise | C | 0.00 | 2,930,482 | 0 | 0 | |
May 06 2021 | HOWL | Werewolf Therapeut ... | RA CAPITAL MANAGEMENT, L.P. | Director | Option Exercise | C | 0.00 | 16,606,068 | 0 | 0 | |
May 06 2021 | HOWL | Werewolf Therapeut ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | P | 16.00 | 105,788 | 1,692,608 | 443,825 | 338 K to 443.8 K (+31.29 %) |
May 06 2021 | HOWL | Werewolf Therapeut ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | C | 0.00 | 338,037 | 0 | 338,037 | 0 to 338 K |
May 06 2021 | HOWL | Werewolf Therapeut ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | P | 16.00 | 1,609,212 | 25,747,392 | 3,524,758 | 1.9 M to 3.5 M (+84.01 %) |
May 06 2021 | HOWL | Werewolf Therapeut ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | C | 0.00 | 1,915,546 | 0 | 1,915,546 | 0 to 1.9 M |
Apr 05 2021 | STSA | Satsuma Pharmaceut ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 5.91 | 192,387 | 1,137,007 | 5,348,241 | 5.2 M to 5.3 M (+3.73 %) |
Apr 05 2021 | STSA | Satsuma Pharmaceut ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 5.91 | 566,011 | 3,345,125 | 566,011 | 0 to 566 K |
Apr 05 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 43.10 | 242,656 | 10,458,474 | 8,539,921 | 8.3 M to 8.5 M (+2.92 %) |
Apr 05 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 43.10 | 755,726 | 32,571,791 | 755,726 | 0 to 755.7 K |
Apr 05 2021 | WVE | Wave Life Sciences ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 5.61 | 768,431 | 4,310,898 | 7,573,613 | 6.8 M to 7.6 M (+11.29 %) |
Apr 05 2021 | WVE | Wave Life Sciences ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 5.61 | 201,594 | 1,130,942 | 201,594 | 0 to 201.6 K |
Apr 05 2021 | SLDB | Solid Biosciences ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 5.53 | 663,720 | 3,670,372 | 11,580,287 | 10.9 M to 11.6 M (+6.08 %) |
Apr 05 2021 | SLDB | Solid Biosciences ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 5.53 | 787,586 | 4,355,351 | 787,586 | 0 to 787.6 K |
Apr 05 2021 | ITOS | iTeos Therapeutics ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 34.18 | 131,364 | 4,490,022 | 3,155,667 | 3 M to 3.2 M (+4.34 %) |
Apr 05 2021 | ITOS | iTeos Therapeutics ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 34.18 | 289,843 | 9,906,834 | 289,843 | 0 to 289.8 K |
Apr 05 2021 | NKTX | Nkarta, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 32.90 | 307,214 | 10,107,341 | 4,589,999 | 4.3 M to 4.6 M (+7.17 %) |
Apr 05 2021 | NKTX | Nkarta, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | J | 32.90 | 260,819 | 8,580,945 | 260,819 | 0 to 260.8 K |
Mar 15 2021 | PHAT | Phathom Pharmaceut ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 43.75 | 710,000 | 31,062,500 | 3,115,008 | 3.8 M to 3.1 M (-18.56 %) |
Feb 11 2021 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | Director | Option Exercise | P | 0.00 | 3,215,434 | 0 | 3,215,434 | |
Feb 11 2021 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | Director | Option Exercise | P | 0.00 | 3,215,434 | 0 | 3,215,434 | |
Feb 09 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Option Exercise | C | 0.00 | 19,230,770 | 0 | 0 | |
Feb 09 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Option Exercise | C | 0.00 | 51,464,036 | 0 | 0 | |
Feb 09 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Option Exercise | C | 0.00 | 3,812,500 | 0 | 0 | |
Feb 09 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Option Exercise | C | 0.00 | 22,637,875 | 0 | 0 | |
Feb 09 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | P | 18.00 | 130,970 | 2,357,460 | 1,825,326 | 1.7 M to 1.8 M (+7.73 %) |
Feb 09 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | P | 18.00 | 2,848,596 | 51,274,728 | 8,297,265 | 5.4 M to 8.3 M (+52.28 %) |
Feb 09 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | C | 0.00 | 1,414,026 | 0 | 1,694,356 | 280.3 K to 1.7 M (+504.41 %) |
Feb 09 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | C | 0.00 | 3,784,120 | 0 | 5,448,669 | 1.7 M to 5.4 M (+227.34 %) |
Feb 09 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | C | 0.00 | 280,330 | 0 | 280,330 | 0 to 280.3 K |
Feb 09 2021 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | C | 0.00 | 1,664,549 | 0 | 1,664,549 | 0 to 1.7 M |
Feb 08 2021 | ITRM | Iterum Therapeutic ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | C | 0.00 | 8,486,000 | 0 | 0 | |
Feb 08 2021 | ITRM | Iterum Therapeutic ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | C | 0.00 | 11,651,597 | 0 | 11,651,597 | 0 to 11.7 M |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.61 | 473,327 | 2,182,037 | 9,880,865 | 9.4 M to 9.9 M (+5.03 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.51 | 10,226 | 46,119 | 9,407,538 | 9.4 M to 9.4 M (+0.11 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.64 | 54,416 | 252,490 | 9,397,312 | 9.3 M to 9.4 M (+0.58 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.61 | 4,525 | 20,860 | 9,342,896 | 9.3 M to 9.3 M (+0.05 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.61 | 58,106 | 267,869 | 9,338,371 | 9.3 M to 9.3 M (+0.63 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.65 | 9,050 | 42,083 | 9,280,265 | 9.3 M to 9.3 M (+0.10 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.69 | 55,204 | 258,907 | 9,271,215 | 9.2 M to 9.3 M (+0.60 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.72 | 45,249 | 213,575 | 9,216,011 | 9.2 M to 9.2 M (+0.49 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.74 | 8,235 | 39,034 | 9,170,762 | 9.2 M to 9.2 M (+0.09 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.74 | 13,031 | 61,767 | 9,162,527 | 9.1 M to 9.2 M (+0.14 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.74 | 16,291 | 77,219 | 9,149,496 | 9.1 M to 9.1 M (+0.18 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.71 | 6,787 | 31,967 | 9,133,205 | 9.1 M to 9.1 M (+0.07 %) |
Nov 06 2020 | ORTX | Orchard Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 4.75 | 14,570 | 69,208 | 9,126,418 | 9.1 M to 9.1 M (+0.16 %) |
Oct 09 2020 | PCVX | Vaxcyte, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 50.69 | 167,661 | 8,498,065 | 5,001,593 | 5.2 M to 5 M (-3.24 %) |
Oct 09 2020 | PCVX | Vaxcyte, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 50.95 | 98,597 | 5,023,527 | 5,169,254 | 5.3 M to 5.2 M (-1.87 %) |
Oct 01 2020 | PCVX | Vaxcyte, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 48.64 | 15,967 | 776,705 | 0 | 16 K to 0 (-100.00 %) |
Oct 01 2020 | PCVX | Vaxcyte, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 50.27 | 124,656 | 6,265,871 | 5,283,818 | 5.4 M to 5.3 M (-2.30 %) |
Oct 01 2020 | PCVX | Vaxcyte, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 52.08 | 80,707 | 4,202,987 | 5,408,474 | 5.5 M to 5.4 M (-1.47 %) |
Sep 29 2020 | PMVP | PMV Pharmaceutical ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | C | 0.00 | 760,265 | 0 | 0 | |
Sep 29 2020 | PMVP | PMV Pharmaceutical ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 18.00 | 950,000 | 17,100,000 | 1,710,265 | 760.3 K to 1.7 M (+124.96 %) |
Sep 29 2020 | PMVP | PMV Pharmaceutical ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | C | 0.00 | 760,265 | 0 | 760,265 | 0 to 760.3 K |
Sep 23 2020 | DYN | Dyne Therapeutics, ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | C | 0.00 | 7,114,905 | 0 | 0 | |
Sep 23 2020 | DYN | Dyne Therapeutics, ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 19.00 | 660,000 | 12,540,000 | 2,805,045 | 2.1 M to 2.8 M (+30.77 %) |
Sep 23 2020 | DYN | Dyne Therapeutics, ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | C | 0.00 | 2,145,045 | 0 | 2,145,045 | 0 to 2.1 M |
Sep 21 2020 | ETNB | 89bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | P | 28.00 | 1,300,000 | 36,400,000 | 4,736,214 | 3.4 M to 4.7 M (+37.83 %) |
Sep 11 2020 | TGTX | TG THERAPEUTICS, I ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 25.81 | 158,589 | 4,092,738 | 12,629,868 | 12.8 M to 12.6 M (-1.24 %) |
Aug 24 2020 | INBX | Inhibrx, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | C | 0.00 | 3,700,634 | 0 | 0 | |
Aug 24 2020 | INBX | Inhibrx, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | C | 0.00 | 2,129,003 | 0 | 2,129,003 | 0 to 2.1 M |
Jul 29 2020 | ITOS | iTeos Therapeutics ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | C | 0.00 | 9,751,773 | 0 | 0 | |
Jul 29 2020 | ITOS | iTeos Therapeutics ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 19.00 | 1,425,000 | 27,075,000 | 4,417,259 | 3 M to 4.4 M (+47.62 %) |
Jul 29 2020 | ITOS | iTeos Therapeutics ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | C | 0.00 | 2,992,259 | 0 | 2,992,259 | 0 to 3 M |
Jul 28 2020 | INZY | Inozyme Pharma, In ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | C | 0.00 | 10,489,510 | 0 | 0 | |
Jul 28 2020 | INZY | Inozyme Pharma, In ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 16.00 | 600,000 | 9,600,000 | 2,003,653 | 1.4 M to 2 M (+42.75 %) |
Jul 28 2020 | INZY | Inozyme Pharma, In ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | C | 0.00 | 1,403,653 | 0 | 1,403,653 | 0 to 1.4 M |
Jul 22 2020 | PAND | Pandion Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | C | 0.00 | 7,184,596 | 0 | 0 | |
Jul 22 2020 | PAND | Pandion Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 18.00 | 361,111 | 6,499,998 | 1,770,023 | 1.4 M to 1.8 M (+25.63 %) |
Jul 22 2020 | PAND | Pandion Therapeuti ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | C | 0.00 | 1,408,912 | 0 | 1,408,912 | 0 to 1.4 M |
Jul 16 2020 | NKTX | Nkarta, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | C | 0.00 | 8,405,656 | 0 | 0 | |
Jul 16 2020 | NKTX | Nkarta, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 18.00 | 3,333,333 | 59,999,994 | 5,605,129 | 2.3 M to 5.6 M (+146.73 %) |
Jul 16 2020 | NKTX | Nkarta, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | C | 0.00 | 2,271,796 | 0 | 2,271,796 | 0 to 2.3 M |
Jul 10 2020 | ETNB | 89bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | P | 27.50 | 275,000 | 7,562,500 | 3,436,214 | 3.2 M to 3.4 M (+8.70 %) |
Jul 02 2020 | RYTM | RHYTHM PHARMACEUTI ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 22.04 | 44,153 | 972,969 | 5,140,408 | 5.2 M to 5.1 M (-0.85 %) |
Jul 02 2020 | RYTM | RHYTHM PHARMACEUTI ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 21.87 | 25,527 | 558,311 | 5,184,561 | 5.2 M to 5.2 M (-0.49 %) |
Jul 02 2020 | RYTM | RHYTHM PHARMACEUTI ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 22.15 | 61,901 | 1,371,237 | 5,210,088 | 5.3 M to 5.2 M (-1.17 %) |
Jun 29 2020 | RYTM | RHYTHM PHARMACEUTI ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 22.19 | 52,049 | 1,154,999 | 5,271,989 | 5.3 M to 5.3 M (-0.98 %) |
Jun 29 2020 | RYTM | RHYTHM PHARMACEUTI ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 23.31 | 86,706 | 2,020,848 | 5,324,038 | 5.4 M to 5.3 M (-1.60 %) |
Jun 29 2020 | RYTM | RHYTHM PHARMACEUTI ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 25.05 | 11,568 | 289,768 | 5,410,744 | 5.4 M to 5.4 M (-0.21 %) |
Jun 29 2020 | VSTM | Verastem, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 1.91 | 1,161,300 | 2,219,941 | 16,142,051 | 17.3 M to 16.1 M (-6.71 %) |
Jun 24 2020 | FMTX | Forma Therapeutics ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | C | 0.00 | 21,437,376 | 0 | 0 | |
Jun 24 2020 | FMTX | Forma Therapeutics ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 20.00 | 4,000,000 | 80,000,000 | 9,011,651 | 5 M to 9 M (+79.81 %) |
Jun 24 2020 | FMTX | Forma Therapeutics ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | C | 0.00 | 5,011,651 | 0 | 5,011,651 | 0 to 5 M |
Jun 24 2020 | FMTX | Forma Therapeutics ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | C | 0.00 | 21,437,376 | 0 | 0 | |
Jun 24 2020 | FMTX | Forma Therapeutics ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 20.00 | 4,000,000 | 80,000,000 | 9,011,651 | 5 M to 9 M (+79.81 %) |
Jun 24 2020 | FMTX | Forma Therapeutics ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | C | 0.00 | 5,011,651 | 0 | 5,011,651 | 0 to 5 M |
Apr 03 2020 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, L.P. | Director | Sell | D | 48.00 | 4,858,260 | 233,196,480 | 0 | 4.9 M to 0 (-100.00 %) |
Mar 31 2020 | PHAT | Phathom Pharmaceut ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 24.55 | 30,600 | 751,264 | 3,707,408 | 3.7 M to 3.7 M (+0.83 %) |
Mar 31 2020 | PHAT | Phathom Pharmaceut ... | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 24.60 | 30,000 | 738,000 | 3,676,808 | 3.6 M to 3.7 M (+0.82 %) |
Mar 17 2020 | IMRA | IMARA Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,741,358 | 0 | 0 | |
Mar 17 2020 | IMRA | IMARA Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | P | 16.00 | 625,000 | 10,000,000 | 1,454,348 | 829.3 K to 1.5 M (+75.36 %) |
Mar 17 2020 | IMRA | IMARA Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | C | 0.00 | 829,348 | 0 | 829,348 | 0 to 829.3 K |
Mar 13 2020 | KALA | Kala Pharmaceutica ... | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | P | 7.89 | 6,337,135 | 49,999,995 | 10,874,613 | 4.5 M to 10.9 M (+139.66 %) |
Jan 24 2020 | THOR | Synthorx, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | U | 68.00 | 9,724,598 | 661,272,664 | 0 | 9.7 M to 0 (-100.00 %) |
Nov 13 2019 | ETNB | 89bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Option Exercise | C | 0.00 | 10,327,777 | 0 | 0 | |
Nov 13 2019 | ETNB | 89bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Option Exercise | C | 0.00 | 10,327,777 | 0 | 0 | |
Nov 13 2019 | ETNB | 89bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | C | 0.00 | 1,661,214 | 0 | 3,161,214 | 1.5 M to 3.2 M (+110.75 %) |
Nov 13 2019 | ETNB | 89bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | C | 0.00 | 1,661,214 | 0 | 3,161,214 | 1.5 M to 3.2 M (+110.75 %) |
Nov 13 2019 | ETNB | 89bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | P | 16.00 | 1,500,000 | 24,000,000 | 1,500,000 | 0 to 1.5 M |
Nov 13 2019 | ETNB | 89bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | P | 16.00 | 1,500,000 | 24,000,000 | 1,500,000 | 0 to 1.5 M |
Sep 17 2019 | STSA | Satsuma Pharmaceut ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | C | 0.00 | 1,340,116 | 0 | 0 | |
Sep 17 2019 | STSA | Satsuma Pharmaceut ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | C | 0.00 | 2,008,409 | 0 | 0 | |
Sep 17 2019 | STSA | Satsuma Pharmaceut ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 15.00 | 1,333,333 | 19,999,995 | 4,681,858 | 3.3 M to 4.7 M (+39.82 %) |
Sep 17 2019 | STSA | Satsuma Pharmaceut ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | C | 0.00 | 1,340,116 | 0 | 3,348,525 | 2 M to 3.3 M (+66.73 %) |
Sep 17 2019 | STSA | Satsuma Pharmaceut ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | C | 0.00 | 2,008,409 | 0 | 2,008,409 | 0 to 2 M |
Jun 13 2019 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | A | 19.88 | 15,000 | 298,200 | 15,000 | |
Apr 15 2019 | SCPH | scPharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | 10% Owner | Buy | P | 2.70 | 389,862 | 1,052,627 | 3,247,005 | 2.9 M to 3.2 M (+13.65 %) |
Jan 28 2019 | WVE | Wave Life Sciences ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 38.00 | 263,158 | 10,000,004 | 7,775,207 | 7.5 M to 7.8 M (+3.50 %) |
Dec 14 2018 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 15.50 | 1,006,452 | 15,600,006 | 4,858,260 | 3.9 M to 4.9 M (+26.13 %) |
Dec 13 2018 | THOR | Synthorx, Inc. | RA CAPITAL MANAGEMENT, LLC | 10% Owner | Option Exercise | C | 0.00 | 5,854,439 | 0 | 0 | |
Dec 13 2018 | THOR | Synthorx, Inc. | RA CAPITAL MANAGEMENT, LLC | 10% Owner | Option Exercise | C | 0.00 | 2,443,794 | 0 | 0 | |
Dec 13 2018 | THOR | Synthorx, Inc. | RA CAPITAL MANAGEMENT, LLC | 10% Owner | Buy | P | 11.00 | 4,545,455 | 50,000,005 | 9,724,598 | 5.2 M to 9.7 M (+87.76 %) |
Dec 13 2018 | THOR | Synthorx, Inc. | RA CAPITAL MANAGEMENT, LLC | 10% Owner | Buy | C | 0.00 | 3,653,908 | 0 | 5,179,143 | 1.5 M to 5.2 M (+239.56 %) |
Dec 13 2018 | THOR | Synthorx, Inc. | RA CAPITAL MANAGEMENT, LLC | 10% Owner | Buy | C | 0.00 | 1,525,235 | 0 | 1,525,235 | 0 to 1.5 M |
Nov 01 2018 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | A | 9.90 | 15,000 | 148,500 | 15,000 | |
Nov 01 2018 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | A | 9.90 | 15,000 | 148,500 | 15,000 | |
Oct 05 2018 | KALA | Kala Pharmaceutica ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 8.25 | 2,424,242 | 19,999,997 | 4,537,478 | 2.1 M to 4.5 M (+114.72 %) |
Oct 05 2018 | KALA | Kala Pharmaceutica ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 8.25 | 2,424,242 | 19,999,997 | 4,537,478 | 2.1 M to 4.5 M (+114.72 %) |
Oct 03 2018 | ARVN | ARVINAS INC. | RA CAPITAL MANAGEMENT, LLC | Option Exercise | C | 0.00 | 947,085 | 0 | 0 | ||
Oct 03 2018 | ARVN | ARVINAS INC. | RA CAPITAL MANAGEMENT, LLC | Option Exercise | C | 0.00 | 6,002,761 | 0 | 0 | ||
Oct 03 2018 | ARVN | ARVINAS INC. | RA CAPITAL MANAGEMENT, LLC | Buy | P | 16.00 | 1,000,000 | 16,000,000 | 3,138,412 | 2.1 M to 3.1 M (+46.76 %) | |
Oct 03 2018 | ARVN | ARVINAS INC. | RA CAPITAL MANAGEMENT, LLC | Buy | C | 0.00 | 291,410 | 0 | 2,138,412 | 1.8 M to 2.1 M (+15.78 %) | |
Oct 03 2018 | ARVN | ARVINAS INC. | RA CAPITAL MANAGEMENT, LLC | Buy | C | 0.00 | 1,847,002 | 0 | 1,847,002 | 0 to 1.8 M | |
Jul 02 2018 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | A | 9.90 | 15,000 | 148,500 | 15,000 | |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | C | 0.00 | 922,950 | 0 | 0 | |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 17.00 | 1,058,824 | 18,000,008 | 2,162,671 | 1.1 M to 2.2 M (+95.92 %) |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | C | 0.00 | 1,103,847 | 0 | 1,103,847 | 0 to 1.1 M |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | C | 0.00 | 922,950 | 0 | 0 | |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 17.00 | 1,058,824 | 18,000,008 | 2,162,671 | 1.1 M to 2.2 M (+95.92 %) |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | C | 0.00 | 1,103,847 | 0 | 1,103,847 | 0 to 1.1 M |
Feb 16 2018 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 6.00 | 2,500,000 | 15,000,000 | 3,851,808 | 1.4 M to 3.9 M (+184.94 %) |
Dec 20 2017 | DRNA | Dicerna Pharmaceut ... | RA CAPITAL MANAGEMENT, LLC | 10% Owner | Option Exercise | M | 0.00 | 76,500 | 0 | 0 | |
Dec 20 2017 | DRNA | Dicerna Pharmaceut ... | RA CAPITAL MANAGEMENT, LLC | 10% Owner | Buy | M | 0.00 | 2,645,442 | 0 | 5,074,013 | 2.4 M to 5.1 M (+108.93 %) |
Nov 15 2017 | WVE | Wave Life Sciences ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 24.00 | 23,398 | 561,550 | 7,512,049 | 7.5 M to 7.5 M (+0.31 %) |
Nov 15 2017 | WVE | Wave Life Sciences ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 23.30 | 400,000 | 9,320,000 | 7,488,651 | 7.1 M to 7.5 M (+5.64 %) |
Oct 16 2017 | KALV | KalVista Pharmaceu ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 8.50 | 850,000 | 7,225,000 | 1,441,070 | 591.1 K to 1.4 M (+143.81 %) |
Sep 29 2017 | KALV | KalVista Pharmaceu ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | A | 6.71 | 6,000 | 40,260 | 6,000 | |
Jul 26 2017 | KALA | Kala Pharmaceutica ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | C | 0.00 | 4,409,170 | 0 | 0 | |
Jul 26 2017 | KALA | Kala Pharmaceutica ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | C | 0.00 | 3,819,444 | 0 | 0 | |
Jul 26 2017 | KALA | Kala Pharmaceutica ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 15.00 | 533,333 | 7,999,995 | 2,113,236 | 1.6 M to 2.1 M (+33.76 %) |
Jul 26 2017 | KALA | Kala Pharmaceutica ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | C | 0.00 | 1,579,903 | 0 | 1,579,903 | 0 to 1.6 M |
Jun 22 2017 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | A | 22.37 | 15,000 | 335,550 | 15,000 | |
May 24 2017 | GTHX | G1 Therapeutics, I ... | RA CAPITAL MANAGEMENT, LLC | Option Exercise | C | 0.00 | 1,682,822 | 0 | 0 | ||
May 24 2017 | GTHX | G1 Therapeutics, I ... | RA CAPITAL MANAGEMENT, LLC | Option Exercise | C | 0.00 | 5,169,916 | 0 | 0 | ||
May 24 2017 | GTHX | G1 Therapeutics, I ... | RA CAPITAL MANAGEMENT, LLC | Buy | P | 15.00 | 400,000 | 6,000,000 | 2,684,244 | 2.3 M to 2.7 M (+17.51 %) | |
May 24 2017 | GTHX | G1 Therapeutics, I ... | RA CAPITAL MANAGEMENT, LLC | Buy | C | 0.00 | 560,940 | 0 | 2,284,244 | 1.7 M to 2.3 M (+32.55 %) | |
May 24 2017 | GTHX | G1 Therapeutics, I ... | RA CAPITAL MANAGEMENT, LLC | Buy | C | 0.00 | 1,723,304 | 0 | 1,723,304 | 0 to 1.7 M | |
Apr 13 2017 | DRNA | Dicerna Pharmaceut ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | J | 3.19 | 76,500 | 244,035 | 76,500 | |
Mar 27 2017 | CBYL | KalVista Pharmaceu ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | A | 7.88 | 12,000 | 94,560 | 12,000 |